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Background
Chinese hamster ovary (CHO) cells are the most widely
used host for large scale production of recombinant
therapeutic proteins. A combination of several gene
editing approaches applied to Novartis proprietary CHO
cell line resulted in a superior cell line with a significant
increase of titer and improved product quality. Inter alia
we have surprisingly identified a key protease responsi-
ble for proteolytic degradation of mainly non-antibody
format therapeutic proteins. The recently published
CHO genome in combination with screening methods
and cell line engineering tools has enabled the develop-
ment of this novel CHO cell line.
Materials and methods
CHO cell lines growing in suspension were cultivated at
36.5 C° and 10% CO2 in shake flasks using a proprie-
tary, chemically defined culture medium. Gene editing
was performed according to manufacturer’s protocols,
cells were single cell sorted using FACS device and sub-
sequently screened for the desired phenotype. Cell
viabilities and growth rates were monitored using an
automated system (ViCell, Beckman Coulter). Cells were
stably transfected by electroporation (Amaxa Nucleofec-
tion system, Lonza, Germany) with expression plasmids
encoding human monoclonal antibodies. This and all
other kits were used according to the manufacturer’s
instructions.
Spike-in experiments were performed in conditioned
medium. Conditioned medium was collected by centri-
fugation of the cells grown for 7/8 days for 15 min at
90 g. After centrifugation, the supernatant was trans-
ferred and passed through a 0.22 μm filter to remove
remaining cell particles from the conditioned medium.
Under these conditions and at this stage of cell growth,
the maximum amounts of secreted proteases are
expected to be active in the cell culture medium without
release of intracellular proteases due to cell death. The
polypeptide of interest was added to the conditioned
medium with a final concentration of 0.7 μM and incu-
bated at 37°C with continuous shaking at 500 rpm.
After incubation, samples were analyzed by SDS-PAGE
followed by Western Blot analysis to determine the
amount of clipping.
Results
Elimination of telomeric region of chromosome 8
Gene expression profiles of high versus low producing
CHO clones were compared to identify genes correlated
with increased titer. Improved production rates were
surprisingly correlating with loss of the telomeric region
of chromosome 8 (figure 1A). Based on this finding
three new parental CHO cell lines lacking this region
were generated and their capability for protein produc-
tion was assessed. After transfection and two consecu-
tive selection steps (geneticin followed by methotrexate
selection) a massive increase of productivity could be
detected for all three new cell lines compared to the ori-
ginal cell line (35 fold increase for G418 selection and 7
fold increase for methotrexate selection, respectively)
(figure 1B). The increased productivity obtained with
the new cell lines is facilitating the supply of early drug
substance material. In addition, significantly more cell
clones with a higher average productivity were obtained
after single cell cloning. This results in reduced efforts
in single cell sorting and the need to screen fewer
clones.
Identification of major clipping protease and gene
knockout using gene editing technologies
Proteolytic activity in cell cultures is derived from endo-
genously expressed proteases. However of the major1Novartis Development Integrated Biologic Profiling, 4002 Basel, Switzerland
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challenge is that more than 700 endogenous proteases
are known. We applied different approaches e.g. a vari-
ety of protease inhibitors, siRNAs and next generation
sequencing approaches to identify the main protease(s)
involved in clipping of therapeutic proteins produced in
CHOK1 derived cell lines (figure 1C).We have surpris-
ingly identified one protease which is mainly responsible
for proteolytic degradation. To eliminate the proteolytic
activity, the protease gene was knocked out using gene
editing technology. To evaluate the effect of the knock-
out cell line, protein candidates of diverse formats
which were degraded in CHO wildtype cells were co-
incubated in conditioned medium derived from knock-
out and wildtype CHO cell lines. No or significant
reduced degradation of the proteins was detected using
the protease knockout cell line (figure 1D).
Conclusions
The combination of the recently published CHO gen-
ome [1-3]with screening methods and cell line engineer-
ing tools has enabled the development of a superior
CHO cell line. Gene expression profile analysis of high
vs. low antibody producing CHO cell lines revealed that
high production is correlated with loss of the telomeric
region of chromosome 8. New parental cell lines lacking
this telomeric region showed increased productivities
after transfection. Additionally the knockout of a sur-
prisingly identified protease eliminates/significantly
reduces proteolytic degradation evaluated with a variety
of therapeutic proteins. In conclusion novel cell line
engineering methods are powerful tools to improve pro-
ductivity and can solve issues in production of therapeu-
tic proteins in biopharmaceutical industry in a short
timeframe with minimal screening effort.
Figure 1 A: BAC hybridisation of relevant region to the large and small chromosome 8. Only the small chromosome 8 contains the
region of interest. B: Comparison of G418 batch and MTX fed-batch titers expressed in the three new CHO cell lines in comparison to CHO-K1
cells. A massive increase of pool productivity could be detected. C: A variety of assays were applied to identify the key protease. These include
broad spectrum protease inhibitors, mass spectrum analysis, next generation sequencing and siRNAs. D: Evaluating proteolytic degradation in
conditioned medium between WT cell line and protease KO cell line
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